(MCK) McKesson - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US58155Q1031
Stock:
Total Rating 67
Risk 79
Buy Signal 0.41
| Risk 5d forecast | |
|---|---|
| Volatility | 23.5% |
| Relative Tail Risk | -8.73% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.62 |
| Alpha | 53.44 |
| Character TTM | |
|---|---|
| Beta | 0.280 |
| Beta Downside | 0.252 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.91% |
| CAGR/Max DD | 1.71 |
EPS (Earnings per Share)
Revenue
Description: MCK McKesson
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners to address challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver solutions to help people get the medicine needed to live healthier lives; and provides medication access and affordability, prescription decision support, prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services, as well as electronic prior authorization services. The Medical-Surgical Solutions segment offers medical-surgical supply distribution, logistics, biomedical maintenance, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, post-acute care facilities, hospital reference labs, and home health care agencies. The International segment delivers medicines, supplies, and information technology solutions to retail pharmacies, hospitals, long-term care centers, clinics and institutions; and provides logistics and distribution services for manufacturers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 4.34b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 9.69 > 1.0 |
| NWC/Revenue: -2.12% < 20% (prev -1.98%; Δ -0.14% < -1%) |
| CFO/TA 0.12 > 3% & CFO 10.48b > Net Income 4.34b |
| Net Debt (5.67b) to EBITDA (6.47b): 0.88 < 3 |
| Current Ratio: 0.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (123.7m) vs 12m ago -2.29% < -2% |
| Gross Margin: 3.37% > 18% (prev 0.04%; Δ 333.7% > 0.5%) |
| Asset Turnover: 512.6% > 50% (prev 484.8%; Δ 27.82% > 0%) |
| Interest Coverage Ratio: 25.04 > 6 (EBITDA TTM 6.47b / Interest Expense TTM 231.0m) |
Altman Z'' 0.89
| A: -0.10 (Total Current Assets 59.70b - Total Current Liabilities 68.13b) / Total Assets 84.19b |
| B: 0.25 (Retained Earnings 20.71b / Total Assets 84.19b) |
| C: 0.07 (EBIT TTM 5.78b / Avg Total Assets 77.64b) |
| D: 0.24 (Book Value of Equity 19.81b / Total Liabilities 84.29b) |
| Altman-Z'' Score: 0.89 = B |
Beneish M -2.88
| DSRI: 0.95 (Receivables 28.21b/25.83b, Revenue 397.96b/344.58b) |
| GMI: 1.10 (GM 3.37% / 3.71%) |
| AQI: 1.10 (AQ_t 0.24 / AQ_t-1 0.21) |
| SGI: 1.15 (Revenue 397.96b / 344.58b) |
| TATA: -0.07 (NI 4.34b - CFO 10.48b) / TA 84.19b) |
| Beneish M-Score: -2.88 (Cap -4..+1) = A |
What is the price of MCK shares?
As of February 25, 2026, the stock is trading at USD 957.36 with a total of 329,088 shares traded.
Over the past week, the price has changed by +1.15%, over one month by +15.82%, over three months by +10.12% and over the past year by +58.71%.
Over the past week, the price has changed by +1.15%, over one month by +15.82%, over three months by +10.12% and over the past year by +58.71%.
Is MCK a buy, sell or hold?
McKesson has received a consensus analysts rating of 4.29.
Therefore, it is recommended to buy MCK.
- StrongBuy: 10
- Buy: 3
- Hold: 3
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the MCK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 980.4 | 2.4% |
| Analysts Target Price | 980.4 | 2.4% |
MCK Fundamental Data Overview February 21, 2026
P/E Trailing = 27.0303
P/E Forward = 21.1416
P/S = 0.2907
P/B = 5.0435
P/EG = 1.1365
Revenue TTM = 397.96b USD
EBIT TTM = 5.78b USD
EBITDA TTM = 6.47b USD
Long Term Debt = 5.42b USD (from longTermDebt, last quarter)
Short Term Debt = 1.42b USD (from shortTermDebt, last quarter)
Debt = 8.62b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.67b USD (from netDebt column, last quarter)
Enterprise Value = 121.33b USD (115.67b + Debt 8.62b - CCE 2.96b)
Interest Coverage Ratio = 25.04 (Ebit TTM 5.78b / Interest Expense TTM 231.0m)
EV/FCF = 12.02x (Enterprise Value 121.33b / FCF TTM 10.10b)
FCF Yield = 8.32% (FCF TTM 10.10b / Enterprise Value 121.33b)
FCF Margin = 2.54% (FCF TTM 10.10b / Revenue TTM 397.96b)
Net Margin = 1.09% (Net Income TTM 4.34b / Revenue TTM 397.96b)
Gross Margin = 3.37% ((Revenue TTM 397.96b - Cost of Revenue TTM 384.53b) / Revenue TTM)
Gross Margin QoQ = 3.47% (prev 3.43%)
Tobins Q-Ratio = 1.44 (Enterprise Value 121.33b / Total Assets 84.19b)
Interest Expense / Debt = 0.73% (Interest Expense 63.0m / Debt 8.62b)
Taxrate = 23.31% (380.0m / 1.63b)
NOPAT = 4.44b (EBIT 5.78b * (1 - 23.31%))
Current Ratio = 0.88 (Total Current Assets 59.70b / Total Current Liabilities 68.13b)
Debt / Equity = -6.64 (negative equity) (Debt 8.62b / totalStockholderEquity, last quarter -1.30b)
Debt / EBITDA = 0.88 (Net Debt 5.67b / EBITDA 6.47b)
Debt / FCF = 0.56 (Net Debt 5.67b / FCF TTM 10.10b)
Total Stockholder Equity = -1.77b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.59% (Net Income 4.34b / Total Assets 84.19b)
RoE = -245.3% (negative equity) (Net Income TTM 4.34b / Total Stockholder Equity -1.77b)
RoCE = 158.2% (EBIT 5.78b / Capital Employed (Equity -1.77b + L.T.Debt 5.42b))
RoIC = 85.84% (NOPAT 4.44b / Invested Capital 5.17b)
WACC = 6.51% (E(115.67b)/V(124.29b) * Re(6.95%) + D(8.62b)/V(124.29b) * Rd(0.73%) * (1-Tc(0.23)))
Discount Rate = 6.95% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.67%
[DCF] Terminal Value 84.32% ; FCFF base≈6.71b ; Y1≈7.00b ; Y5≈8.06b
[DCF] Fair Price = 1578 (EV 198.94b - Net Debt 5.67b = Equity 193.28b / Shares 122.5m; r=6.51% [WACC]; 5y FCF grow 4.56% → 2.90% )
EPS Correlation: 85.51 | EPS CAGR: 13.39% | SUE: 0.44 | # QB: 0
Revenue Correlation: 96.68 | Revenue CAGR: 13.47% | SUE: 0.08 | # QB: 0
EPS next Quarter (2026-06-30): EPS=9.72 | Chg7d=-0.020 | Chg30d=-0.039 | Revisions Net=-2 | Analysts=7
EPS next Year (2027-03-31): EPS=44.22 | Chg7d=+0.014 | Chg30d=+0.417 | Revisions Net=+14 | Growth EPS=+13.3% | Growth Revenue=+8.2%
[Analyst] Revisions Ratio: -0.33 (2 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.3% (Discount Rate 7.9% - Earnings Yield 3.7%)
[Growth] Growth Spread = +3.6% (Analyst 7.9% - Implied 4.3%)
P/E Forward = 21.1416
P/S = 0.2907
P/B = 5.0435
P/EG = 1.1365
Revenue TTM = 397.96b USD
EBIT TTM = 5.78b USD
EBITDA TTM = 6.47b USD
Long Term Debt = 5.42b USD (from longTermDebt, last quarter)
Short Term Debt = 1.42b USD (from shortTermDebt, last quarter)
Debt = 8.62b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.67b USD (from netDebt column, last quarter)
Enterprise Value = 121.33b USD (115.67b + Debt 8.62b - CCE 2.96b)
Interest Coverage Ratio = 25.04 (Ebit TTM 5.78b / Interest Expense TTM 231.0m)
EV/FCF = 12.02x (Enterprise Value 121.33b / FCF TTM 10.10b)
FCF Yield = 8.32% (FCF TTM 10.10b / Enterprise Value 121.33b)
FCF Margin = 2.54% (FCF TTM 10.10b / Revenue TTM 397.96b)
Net Margin = 1.09% (Net Income TTM 4.34b / Revenue TTM 397.96b)
Gross Margin = 3.37% ((Revenue TTM 397.96b - Cost of Revenue TTM 384.53b) / Revenue TTM)
Gross Margin QoQ = 3.47% (prev 3.43%)
Tobins Q-Ratio = 1.44 (Enterprise Value 121.33b / Total Assets 84.19b)
Interest Expense / Debt = 0.73% (Interest Expense 63.0m / Debt 8.62b)
Taxrate = 23.31% (380.0m / 1.63b)
NOPAT = 4.44b (EBIT 5.78b * (1 - 23.31%))
Current Ratio = 0.88 (Total Current Assets 59.70b / Total Current Liabilities 68.13b)
Debt / Equity = -6.64 (negative equity) (Debt 8.62b / totalStockholderEquity, last quarter -1.30b)
Debt / EBITDA = 0.88 (Net Debt 5.67b / EBITDA 6.47b)
Debt / FCF = 0.56 (Net Debt 5.67b / FCF TTM 10.10b)
Total Stockholder Equity = -1.77b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.59% (Net Income 4.34b / Total Assets 84.19b)
RoE = -245.3% (negative equity) (Net Income TTM 4.34b / Total Stockholder Equity -1.77b)
RoCE = 158.2% (EBIT 5.78b / Capital Employed (Equity -1.77b + L.T.Debt 5.42b))
RoIC = 85.84% (NOPAT 4.44b / Invested Capital 5.17b)
WACC = 6.51% (E(115.67b)/V(124.29b) * Re(6.95%) + D(8.62b)/V(124.29b) * Rd(0.73%) * (1-Tc(0.23)))
Discount Rate = 6.95% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.67%
[DCF] Terminal Value 84.32% ; FCFF base≈6.71b ; Y1≈7.00b ; Y5≈8.06b
[DCF] Fair Price = 1578 (EV 198.94b - Net Debt 5.67b = Equity 193.28b / Shares 122.5m; r=6.51% [WACC]; 5y FCF grow 4.56% → 2.90% )
EPS Correlation: 85.51 | EPS CAGR: 13.39% | SUE: 0.44 | # QB: 0
Revenue Correlation: 96.68 | Revenue CAGR: 13.47% | SUE: 0.08 | # QB: 0
EPS next Quarter (2026-06-30): EPS=9.72 | Chg7d=-0.020 | Chg30d=-0.039 | Revisions Net=-2 | Analysts=7
EPS next Year (2027-03-31): EPS=44.22 | Chg7d=+0.014 | Chg30d=+0.417 | Revisions Net=+14 | Growth EPS=+13.3% | Growth Revenue=+8.2%
[Analyst] Revisions Ratio: -0.33 (2 Up / 4 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.3% (Discount Rate 7.9% - Earnings Yield 3.7%)
[Growth] Growth Spread = +3.6% (Analyst 7.9% - Implied 4.3%)